News and Press Releases
Press releases
Theralase® 1Q2025 Financial Statements
Press ReleaseTheralase® reported Q1 2025 results showing lower revenue and increased R&D expenses, ongoing Study II enrollment with promising bladder cancer interim data, continued HSV treatment development, and plans for Rutherrin® clinical trials...
CORRECTION FROM SOURCE: Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseTheralase® will present preclinical data comparing radiation-activated Rutherrin® versus radiation alone at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits; clinical trials for various cancers begin...
Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseTheralase®’s Rutherrin® is 100x more effective than radiation alone in preclinical cancer models, showing tumor targeting, immune activation, and improved survival; Phase I/II clinical trials start early 2026 targeting multiple cancers....
Theralase® Provides Corporate Update
Press ReleaseTheralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research...
Theralase® Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Press ReleaseTheralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for...
Theralase® Discovers New Mechanism of Action of Lead Drug
Press ReleaseTheralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closes $419,124 private placement financing by issuing 1,995,829 units at CAD 0.21 each, with warrants exercisable at CAD 0.32 for 5 years. Funds will support Phase II bladder cancer trials, HSV treatment R&D, Rutherrin®...
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Press ReleaseRuvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms...
Ruvidar Demonstrates 7 Year Complete Response
Press ReleaseA BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat...
Ruvidar Effective in the Treatment of Herpes
Press ReleaseRuvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
